	US 12,162,958 B2
	Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
David Stover, Encino, CA (US); Sherie Morrison, Los Angeles, CA (US); Alex Vasuthasawat, Los Angeles, CA (US); Kham Trinh, Porter Ranch, CA (US); and George Ayoub, Los Angeles, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Qwixel Therapeutics LLC, Los Angeles, CA (US)
Filed on Sep. 14, 2023, as Appl. No. 18/467,206.
Application 18/467,206 is a continuation of application No. 17/465,727, filed on Sep. 2, 2021, granted, now 11,795,198.
Application 17/465,727 is a continuation of application No. 16/849,889, filed on Apr. 15, 2020, granted, now 11,136,353, issued on Oct. 5, 2021.
Claims priority of provisional application 62/920,140, filed on Apr. 15, 2019.
Prior Publication US 2024/0076316 A1, Mar. 7, 2024
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01); A61K 47/65 (2017.01); A61P 35/00 (2006.01)

CPC C07K 7/08 (2013.01) [A61K 47/65 (2017.08); A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

29 Claims

1. A composition, comprising a fusion protein which comprises

(i) a polypeptide comprising a cleavable linker (SEQ ID NO: 16) and a polypeptide mask (SEQ ID NO: 15), wherein said polypeptide sequence masks the activity of a Type-I interferon (IFN) and;

(ii) an antibody that binds to a tumor associated antigen.